首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

2051214

流感疫苗市場：依疫苗類型、價數、給藥途徑、年齡層、技術、通路和地區分類。

Influenza Vaccines Market, By Vaccine Type, By Valency, By Route of Administration, By Age Group, By Technology, By Distribution Channel, By Geography

出版日期: 2026年04月01日 | 出版商:

Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到2026年，流感疫苗市場規模將達到95.8億美元，到2033年將達到158.9億美元。預計從2026年到2033年，其複合年成長率將達到7.5%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	95.8億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	7.50%	2033年市場規模預測：	158.9億美元

幾十年來，流感疫苗一直是醫療保健的重要組成部分。由於流感病毒具有不斷變異和進化的能力，因此每年都需要研發最新的疫苗。疫苗的作用機制是增強人體對這些不斷進化的病毒的免疫反應。疫苗旨在提供針對三到四種病毒株的免疫力（取決於特定流感季節使用的疫苗類型），這些病毒株是透過監測和其他科學研究確定的，最有可能在下一個流感季節在特定地區流行。近年來，全球流感疫苗市場穩步成長，這主要得益於人們對季節性疫苗接種意識的提高、新技術的引入、醫療機構不斷完善的疫苗接種指南以及世界各國政府加強支持。

市場動態

全球流感疫苗市場成長受多種因素驅動，包括流感疫情的蔓延、世界衛生組織製定的疫苗接種指南的廣泛應用、公眾對疫苗接種意識的提高、新產品的上市、重組疫苗日益受到青睞以及主要公司企業發展的擴張。然而，市場成長也面臨許多挑戰，例如四價流感疫苗研發成本高昂、新疫苗核准監管嚴格以及流感病毒株抗原突變導致的疫苗抗藥性問題。由於新興國家醫療基礎設施的改善和居民可支配收入的增加，市場參與者在這些國家發現了商機。此外，製造商也致力於研發能夠提供多種流感病毒株的持久保護的通用流感疫苗。

本次調查的主要特點

本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的重要見解。
本研究根據以下參數對全球流感疫苗市場的主要參與者進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。
透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份全球流感疫苗市場報告的目標受群眾外包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師等產業相關人員。
透過分析全球流感疫苗市場時所使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 南非
- 中非
- 北非

第11章競爭格局

熱圖分析
市佔率分析
- CSL Seqirus
- GlaxoSmithKline plc
- Sanofi
- AstraZeneca
- FluGen, Inc.
- Moderna, Inc.
- Biocryst Pharmaceuticals Inc.
- CPL Biologicals Pvt. Ltd.
- CureVac AG
- OSIVAX
- Solaris Vaccines
- Pfizer
- Daiichi Sankyo
- Bharat Biotech
- Sinovac Biotech
- Solaris Vaccines

第12章分析師觀點

機會分析
分析師意見
Coherent Opportunity Map

第13章參考文獻與調查方法

參考
調查方法

簡介目錄

Product Code: CMI1705

Influenza Vaccines Market is estimated to be valued at USD 9.58 Bn in 2026 and is expected to reach USD 15.89 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.5% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 9.58 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	7.50%	2033 Value Projection:	USD 15.89 Bn

Influenza vaccines have been an important element of preventive healthcare for decades. The influenza viruses have the ability to mutate and evolve regularly, necessitating the development of updated vaccines each year. The vaccines work to boost the body's immune response to these changing viruses. They are designed to immunize against the three or four strains (depending on the vaccine type used for a particular flu season) that surveillance and other scientific studies have determined are most likely to be in circulation for the upcoming flu season in any given region. The global influenza vaccines market has witnessed steady growth over the past few years due to the growing awareness about seasonal vaccination, introduction of novel technologies, expansion of vaccination guidelines by healthcare organizations, and rising government support worldwide.

Market Dynamics

The global influenza vaccines market growth is driven by various factors such as the increasing prevalence of influenza, growing adoption of vaccination guidelines set by international health organizations, rising awareness about vaccination, new product launches, growing preference for recombinant technology vaccines, and expansion in geographical reach of major players. However, the market growth can be challenging due to high R&D costs involved for development of quadrivalent influenza vaccines, stringent regulatory guidelines for approval of new vaccines and vaccine resistance arising due to antigenic drift of influenza virus strains. The market players see opportunities in emerging countries owing to improving healthcare infrastructure and rising disposable incomes. Manufacturers are also working on the development of universal influenza vaccine with durable protection against multiple flu strains.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global influenza vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study includes Seqirus, GlaxoSmithKline plc, Sanofi, AstraZeneca, FluGen Inc., Moderna Inc., Biocryst Pharmaceuticals Inc., CPL Biologicals Pvt. Ltd., CureVac AG, OSIVAX, Solaris Vaccines, Pfizer, CSL, Daiichi Sankyo, Bharat Biotech, and Sinovac Biotech.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global influenza vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global influenza vaccines market.

Market Segmentation

Vaccine Type Insights (Revenue, USD Bn, 2026 - 2033)
Inactivated
Live Attenuated
Valency Insights (Revenue, USD Bn, 2026 - 2033)
Quadrivalent
Trivalent
Route of Administration Insights (Revenue, USD Bn, 2026 - 2033)
Injection
Nasal Spray
Age Group Insights (Revenue, USD Bn, 2026 - 2033)
Pediatrics
Adults
Technology Insights (Revenue, USD Bn, 2026 - 2033)
Egg-Based Flu Vaccines
Cell Culture-Based Flu Vaccines
Recombinant Flu Vaccines
Distribution Channel Insights (Revenue, USD Bn, 2026 - 2033)
Public
Private
Regional Insights (Revenue, USD Bn, 2026 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
CSL Seqirus
GlaxoSmithKline plc
Sanofi
AstraZeneca
FluGen Inc.
Moderna Inc.
Biocryst Pharmaceuticals Inc.
CPL Biologicals Pvt. Ltd.
CureVac AG
OSIVAX
Solaris Vaccines
Pfizer
Daiichi Sankyo
Bharat Biotech
Sinovac Biotech

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Vaccine Type
- Market Snapshot, By Valency
- Market Snapshot, By Route of Administration
- Market Snapshot, By Age Group
- Market Snapshot, By Technology
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunity
Impact Analysis
Key Developments
Industry Trends
Regulatory Scenario
Recent Product Approval/Launches
PEST Analysis
Porter's Analysis

4. Global Influenza Vaccines Market, By Vaccine Type, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Inactivated
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Live Attenuated
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

5. Global Influenza Vaccines Market, By Valency, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Quadrivalent
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Trivalent
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

6. Global Influenza Vaccines Market, By Route of Administration, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Nasal Spray
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Global Influenza Vaccines Market, By Age Group, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Pediatrics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

8. Global Influenza Vaccines Market, By Technology, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Egg-Based Flu Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Cell Culture-Based Flu Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Recombinant Flu Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

9. Global Influenza Vaccines Market, By Distribution Channel, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Public
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Private
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

10. Global Influenza Vaccines Market, By Region, 2021 - 2033 (USD Bn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033(%)
- Y-o-Y Growth Analysis, For Regions, 2021 - 2033
- Regional Trends
North America
- Market Size and Forecast, By Vaccine Type, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Valency, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033 (USD Bn)
  - U.S.
  - Canada
Latin America
- Market Size and Forecast, By Vaccine Type, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Valency, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033 (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Market Size and Forecast, By Vaccine Type, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Valency, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033 (USD Bn)
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Size and Forecast, By Vaccine Type, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Valency, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033 (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Vaccine Type, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Valency, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033 (USD Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Market Size and Forecast, By Vaccine Type, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Valency, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Region/Country, 2021 - 2033 (USD Bn)
  - South Africa
  - Central Africa
  - North Africa

11. Competitive Landscape

Heat Map Analysis
Market Share Analysis
- CSL Seqirus
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- GlaxoSmithKline plc
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Sanofi
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- AstraZeneca
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- FluGen, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Moderna, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Biocryst Pharmaceuticals Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- CPL Biologicals Pvt. Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- CureVac AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- OSIVAX
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Solaris Vaccines
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Pfizer
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Daiichi Sankyo
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Bharat Biotech
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Sinovac Biotech
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Solaris Vaccines
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies